Kailera Therapeutics (KLRA) Stock Analysis

What Kailera Therapeutics does

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Key metrics

ETFs linked to KLRA

Broad-market and Healthcare sector ETFs an investor holding Kailera Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how KLRA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Kailera Therapeutics?

Kailera Therapeutics trades under the ticker KLRA on NASDAQ.

Which exchange is KLRA listed on?

KLRA is listed on NASDAQ.

What sector does Kailera Therapeutics operate in?

Kailera Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze KLRA in a portfolio?

PortView shows KLRA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.